Edition:
United Kingdom

Celyad SA (CYAD.BR)

CYAD.BR on Brussels Stock Exchange

19.23EUR
7 Dec 2018
Change (% chg)

-- (--)
Prev Close
€19.23
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
31,136
52-wk High
€39.94
52-wk Low
€18.26

Latest Key Developments (Source: Significant Developments)

Celyad Ended Q3 With 55.9 Million Euros In Cash, Cash Equivalents And Short-Term investments
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - CELYAD SA ::ENDED Q3 WITH EUR 55.9 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS.CONFIRMS ITS PREVIOUS GUIDANCE THAT EXISTING CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS SHOULD BE SUFFICIENT UNTIL MID-2020.  Full Article

Celyad: Update On CYAD-01 Solid Tumor Clinical Program
Friday, 9 Nov 2018 

Nov 9 (Reuters) - CELYAD SA ::STANDALONE CYAD-01 WITHOUT PRECONDITIONING LEADS TO DISEASE STABILIZATION IN THREE OUT OF 11 METASTATIC COLORECTAL CANCER (MCRC) PATIENTS IN THINK PHASE 1 TRIAL.PRELIMINARY SAFETY DATA FROM THINK CYFLU COHORT, EVALUATING CYAD-01 WITH PRECONDITIONING, REMAINS ENCOURAGING WITH IMPROVEMENT IN CYAD-01 KINETICS.OVERALL, FIVE OUT OF SEVEN (71%) PATIENTS ACHIEVED MEANINGFUL DECREASE IN BONE MARROW BLASTS.SHRINK PHASE 1 TRIAL UPDATE: INITIAL ACTIVITY RESULTS ASSESSED BY PATHOLOGICAL RESPONSE CRITERIA SHOWED ALL THREE PATIENTS ACHIEVED AN OBJECTIVE CLINICAL RESPONSE.SHRINK PHASE 1 TRIAL UPDATE: CONCURRENT TREATMENT OF CYAD-01 WITH FOLFOX CHEMOTHERAPY APPEARS TO BE WELL TOLERATED.SHRINK PHASE 1 TRIAL UPDATE: HE EXPANSION OF PERIPHERAL CYAD-01 CELLS WITH A CONCURRENT ADMINISTRATION OF FOLFOX CHEMOTHERAPY IS SIMILAR TO THE ONE OBSERVED WITH THE STANDALONE CYAD-01.SHRINK PHASE 1 TRIAL UPDATE: FULL DATA FROM THE SHRINK PHASE 1 TRIAL ARE EXPECTED IN MID-2019.THINK CYFLU PHASE 1 COHORT UPDATE: TREATMENT WITH CYAD-01 FOLLOWING STANDARD PRECONDITIONING REGIMEN OF CYFLU WAS WELL TOLERATED.THINK CYFLU PHASE 1 COHORT UPDATE: PRELIMINARY TRANSLATIONAL DATA SUGGEST AN IMPROVEMENT IN THE CELL EXPANSION OF CYAD-01 INDUCED BY THE CYFLU PRECONDITIONING..THINK CYFLU PHASE 1 COHORT UPDATE: FULL DATA FROM THE THINK CYFLU PHASE 1 COHORT ARE EXPECTED IN MID-2019..  Full Article

Celyad Appoints Filippo Petti As Chief Financial Officer
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - CELYAD SA ::CELYAD APPOINTS FILIPPO PETTI AS CHIEF FINANCIAL OFFICER.MR. PETTI’S APPOINTMENT WILL BE EFFECTIVE SEPTEMBER 3RD, 2018.MR. JEANMART REMAINING AS AN ADVISOR THROUGH DECEMBER 3(ST), 2018.  Full Article

Celyad Announces FDA Acceptance Of IND Application For CYAD-101
Tuesday, 24 Jul 2018 

July 24 (Reuters) - CELYAD SA ::CELYAD ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR CYAD-101, A FIRST-IN-CLASS NON-GENE EDITED ALLOGENEIC CAR-T CANDIDATE.FDA ACCEPTANCE OF IND FOR WORLD'S FIRST NON-GENE EDITED ALLOGENEIC CAR-T CLINICAL PROGRAM.CELYAD ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR CYAD-101, A FIRST-IN-CLASS NON-GENE EDITED ALLOGENEIC CAR-T CANDIDATE.FIRST OF A FAMILY OF NON-GENE EDITED ALLOGENEIC CAR-T, TARGETING COLORECTAL CANCER TO BUILD ON EXPERIENCE FROM SHRINK AUTOLOGOUS CAR T PROGRAM.  Full Article

Celyad Announces FDA Acceptance Of Ind Application For Cyad-101
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Celyad SA ::CELYAD ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR CYAD-101, A FIRST-IN-CLASS NON-GENE EDITED ALLOGENEIC CAR-T CANDIDATE.  Full Article

Celyad Announces Pricing Of 47.3 Million Dollars Global Offering
Thursday, 17 May 2018 

May 17 (Reuters) - CELYAD SA ::CELYAD ANNOUNCES PRICING OF $47.3 MILLION GLOBAL OFFERING.PRICING OF A GLOBAL OFFERING OF 1,800,000 ORDINARY SHARES.1,276,087 ORDINARY SHARES IN EUROPE AND CERTAIN COUNTRIES OUTSIDE OF US AND CANADA IN CONCURRENT PRIVATE PLACEMENT AT PRICE OF EUR 22.29PER SHARE.523,913 ORDINARY SHARES IN FORM OF AMERICAN DEPOSITARY SHARES (ADSS) OFFERED IN UNITED STATES, CANADA AND CERTAIN COUNTRIES OUTSIDE OF EUROPE AT PRICE PER ADS OF USD 26.28.  Full Article

Celyad To Present Updates On CYAD-01 At American Association For Cancer Research Annual Meeting
Thursday, 29 Mar 2018 

March 29 (Reuters) - CELYAD SA ::CELYAD TO PRESENT UPDATES ON CYAD-01 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2018.‍PRECLINICAL STUDY SHOWS ADDING CD28 OR 4-1BB TO CYAD-01 BRINGS NO BENEFIT FOR IN VITRO ACTIVITY OF RECEPTOR​.TO PRESENT UPDATE FROM THINK TRIAL, NEW SHRINK AND LINK TRIALS IN METASTATIC COLORECTAL CANCER​.‍THINK TRIAL: PRELIMINARY EVIDENCE OF NKG2D CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY (CYAD-01) CLINICAL ACTIVITY​.  Full Article

Celyad ends Q3 with EUR 40 million in cash, confirms previous guidance
Friday, 17 Nov 2017 

Nov 17 (Reuters) - CELYAD SA ::ENDED THE QUARTER WITH EUR 40 MILLION IN CASH.CONFIRMS ITS PREVIOUS GUIDANCE THROUGH TO THE FIRST HALF 2019.  Full Article

Celyad reports promising early results at 1st dose level of solid arm of THINK trial
Monday, 19 Jun 2017 

June 19 (Reuters) - CELYAD SA ::CELYAD REPORTS PROMISING EARLY RESULTS AT FIRST DOSE LEVEL OF THE SOLID ARM OF THE THINK TRIAL.TWO METASTATIC COLORECTAL CANCER PATIENTS REPORTED AS STABLE DISEASE AT 3-MONTH FOLLOW-UP(REMOVES EXTRANEOUS WORDS).NO TOXICITY SIGNALS REPORTED UP TO NOW.  Full Article